News Moderna to relocate its UK HQ to London's Tribeca Moderna has firmed up its commitment to the UK by taking a lease on a new headquarters at Tribeca, in the heart of the London Knowledge Quarter.
News Novartis' pelacarsen fail raises questions for other drugs The data from Novartis' disappointing cardiovascular outcomes trial with Lp(a)-targeting pelacarsen have been revealed, leaving cardiologists puzzled.
News Lilly partners with Hims & Hers on obesity drug sales Eli Lilly has signed an agreement with Hims & Hers that will see its weight-loss therapies sold directly on the telehealth company's platform.
News Inflammation-focused Rezera sets terms for IPO Rezera, formerly known as NodThera, has announced the terms of its planned IPO, hoping to raise upwards of $200m for its NLRP3 inhibitor pipeline.
News Moderna, Oxford Uni Ebola jabs backed for pivotal testing Two more Ebola vaccines are set to be added to a trial in the Democratic Republic of the Congo (DRC), currently battling its largest-ever outbreak.
News UK pilots shorter NICE appraisal for new medicines NICE and NHS England are piloting a shorter initial assessment process for promising new medicines, aiming to slash times from 12 to six months.
News Angelini Pharma's R&D chief heads for the exit Dr Rafal Kaminski's near five-year tenure as chief scientific officer of Italy's Angelini Pharma will come to an end in the next couple of weeks.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.